Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 6/20 | 1.00 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | PTPRF | P10586 | 1/20 | 0.44 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27352636 | 0.80 | PTPRC (0.67) | PTPRCCASP3CA9CA1CA2 | |
| SCHEMBL9560733 | 0.80 | PTPRC (0.66) | PTPRCCASP3CA9CA1CA2 | |
| SCHEMBL9295482 | 0.77 | PTPRC (0.62) | PTPRCCA9CA1CA2CA12 | |
| SCHEMBL9769488 | 0.75 | PTPRC (0.60) | PTPRCCASP3CA9CA1CA2 | |
| SCHEMBL13550874 | 0.75 | PTPRC (0.60) | PTPRCCASP3CA9CA1CA2 | |
| SCHEMBL11846453 | 0.75 | PTPRC (0.60) | PTPRCCASP3CA9CA1CA2 | |
| SCHEMBL9769408 | 0.75 | PTPRC (0.60) | PTPRCCASP3CA9CA1CA2 | |
| SCHEMBL23529899 | 0.75 | PTPRC (0.60) | PTPRCCASP3CA9CA1CA2 | |
| SCHEMBL6236495 | 0.74 | PTPRC (1.00) | PTPRCPTPN1PDK2ALDH1A1KDM4E | |
| SCHEMBL68289 | 0.73 | CA1 (0.61) | PTPRCCASP3CA9CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939896-B2 | Naphthalenedione derivatives; treating autoimmune diseases and organ graft rejection | ASTRAZENECA AB (SE) | 2005-09-06 | — | — | US | claimed |
| EP-1259231-B1 | NAPHTHOQUINONE DERIVATIVES AS CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2005-05-25 | — | — | EP | claimed |
| US-20030119897-A1 | Cd45 inhibitors | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | US | claimed |
| EP-1259231-A2 | NAPHTHOQUINONE DERIVATIVES AS CD45 INHIBITORS | AstraZeneca AB (SE) | 2002-11-27 | — | — | EP | claimed |
| WO-2001045681-A2 | NAPHTHOQUINONE DERIVATIVES AS CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | claimed |
| US-20180311356-A1 | METHOD TO INHIBIT ENDOTHELIAL-TO-MESENCHYMAL TRANSITION | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2018-11-01 | — | — | US | disclosed |
| WO-2017070194-A1 | METHOD TO INHIBIT ENDOTHELIAL-TO-MESENCHYMAL TRANSITION | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-04-27 | — | — | WO | disclosed |
| US-6939896-B2 | Naphthalenedione derivatives; treating autoimmune diseases and organ graft rejection | ASTRAZENECA AB (SE) | 2005-09-06 | — | — | US | disclosed |
| EP-1259231-B1 | NAPHTHOQUINONE DERIVATIVES AS CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2005-05-25 | — | — | EP | disclosed |
| US-20030119897-A1 | Cd45 inhibitors | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | US | disclosed |
| EP-1259231-A2 | NAPHTHOQUINONE DERIVATIVES AS CD45 INHIBITORS | AstraZeneca AB (SE) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001045681-A2 | NAPHTHOQUINONE DERIVATIVES AS CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119897-A1 | Cd45 inhibitors | PTPRC, CD2, HLA-C | PTPRC 1/4885CASP3 1519/4885CA9 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.